very nice so far.

New Post Public Reply Private Reply Replies (1) Message Board
joey68
213
very nice so far.

Bulova Technologies Group Inc. (BTGI) Stock Research Links

BTGI Board Company Profile Buy Rating Time & Sales News Filings Financials
View My Board Here:
http://investorshangout.com/Joeys-Investment-Board-91611/


Invite Only

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.

Disclaimer:
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator of the username Joey68.

Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.

There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.

ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice, and are NOT designed to substitute the expertise and judgment of a professional. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in the above post.
I am NOT a professional.
I do NOT work for you.
My posts are NOT investment advice. I am not paid to post.
There is no correlation between the number of posts I write per day and your assumed success of a company.
It is NOT my responsibility to inform you of my own personal investment decisions.
It is NOT my responsibility to inform you when it is time for you to buy, hold, and/or sell a position.
I have no control over, and am not responsible for the actions of others who copy, store, edit, change, prepare any derivative work of or alter in any way any of the content provided in my posts.
Errors and Omissions expected. The writer of the above post accepts no liability or responsibility for any errors or omissions contained in the above post or contained within this Disclaimer.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties. These links are provided for informational purposes only and are NOT endorsed by the writer of the above post. The writer of the above post has no control over the contents of any linked website and bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
The writer of the above post makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by, or the information contained on these websites.
The writer of the above post accepts no liability for any damage or loss, however caused, in connection with the use of or reliance on any information, material, products, or services contained on or accessed through any such linked websites.

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sun Pharma's UNLOXCYT Gains NCCN Category 2A Nod

Updated Category News Views 6

UNLOXCYT: A New Player in Cancer Treatment Well, here's a notch up for Sun Pharma. Their UNLOXCYT® (cosibelimab-ipdl) just got a Category 2A Preferred Designation from the NCCN for locally advanced cutaneous squamous cell carcinoma (laCSCC) patients who can't opt for surgery or radiation. And if you know anything about cancer treatment guidelines, you know that's a big...

Continue Reading
Chemours Faces Heat: 18.63% Stock Drop Jolts Investors

Updated Category News Views 0

Investors Rattled by Chemours' Stark Drop One moment, you're cruising along with the market, and the next, news hits like a brick. That’s what investors in The Chemours Company (NYSE: CC) faced when shares nosedived 18.63% after some unsettling revelations. Let's peel back the layers and see what's got everyone in a tizzy. What's Behind the Lawsuit? Securities lawsuits...

Continue Reading
King City Gardens Debuts Third Dispensary in Cincinnati

Updated Category News Views 2

Every corner of Cincinnati’s cannabis scene just got a little busier with King City Gardens opening up shop in Colerain Township. This move marks their third Garden Dispensary in Greater Cincinnati. It’s not just about adding another location, though. It’s King City’s way of cementing their local roots deeper into the city’s soil, rolling out a mix of...

Continue Reading
Call to Action: Make Disease Cure the Top Election Issue

Updated Category News Views 3

A Call for Congressional Accountability The American Center for Cures is banging the drum for change, and they're banging it loud. Founded by Lou Weisbach, this group has come out swinging, urging Americans to slap disease onto the ballot in the midterms. Why? Because dealing with Alzheimer's, diabetes, heart disease, and cancer every year rips a whopping $1.1 trillion...

Continue Reading
LBT Unveils Game-Changing Cyclotron for Medical Advances

Updated Category News Views 17

Unveiling the LB-30 Cyclotron at EANM 2026 Life in nuclear medicine never stands still, and once again, Longevous Beamtech (LBT) is stirring the pot with its brand-new LB-30 series medical cyclotron. They rolled out this high-powered beast at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM 2026) in Vienna. Leaning into the 30 MeV energy...

Continue Reading
Saddleback's Bold Doula Program: A Game Changer

Updated Category News Views 5

Revolutionizing Maternity Support at Saddleback Saddleback Medical Center in Laguna Hills, California, is stirring the waters with its groundbreaking expansion in maternity services. For the first time, an Orange County hospital—The Women’s Hospital at MemorialCare Saddleback Medical Center—is offering complimentary, around-the-clock in-house doulas. Not a luxury,...

Continue Reading
Sun Home Saunas Earns Top Workplace Honors in Retail

Updated Category News Views 0

In an age where corporate values often seem like lip service, Sun Home Saunas is showing the world what truly being a great place to work means—and they're getting recognized for it. Fortune has placed the sauna and cold plunge company at No. 17 on its 2026 Best Workplaces in Retail list. This ain't just fluff. We're talking about real employees, 100% of them, touting...

Continue Reading
Geothermal Energy Gets Boost with GRMS Adoption

Updated Category News Views 4

Geothermal's Big Leap with the GRMS The oil and gas sector didn't explode overnight—it leapt due to a consistent, standardized language that spoke to investors like a charm. Now, the geothermal industry is borrowing a page from this book of success with the Geothermal Resources Management System (GRMS). Finally, a framework not just built on hope and hot air, but...

Continue Reading
Duolingo Faces Investor Legal Battle Over Stock Decline

Updated Category News Views 5

Doughnut-Sized Dilemma for Duolingo Investors Falling stock prices are nothing new, but when Duolingo (NASDAQ: DUOL) tumbles 25.49% and a securities fraud class action tags along, eyebrows raise. Folks invested between May 2, 2025, and February 26, 2026, might want to dig deeper. Why? Because the alleged deception has unraveled any potential optimism these shareholders...

Continue Reading
Spire's Year-End Call: Eyes on Earnings & Guidance

Updated Category News Views 9

Anticipation Builds for Spire's Upcoming Earnings Call If you're keen on natural gas and the energy sector, keep a firm grip on your coffee cup because Spire Inc. (NYSE: SR) is about to spill the beans on their fiscal 2026 financials. Mark your calendars for November 17. Whether you're tuning in via phone or hitching a ride on the webcast, you're in for an earful. Time...

Continue Reading